Antithrombin alfa - rEVO Biologics
Alternative Names: Antithrombin III recombinant human; Antithrombin III transgenic; ATryn; Recombinant human antithrombin III; rhATIII; Transgenic antithrombin IIILatest Information Update: 25 Sep 2021
At a glance
- Originator GTC Biotherapeutics
- Developer GTC Biotherapeutics; Knight Therapeutics; LEO Pharma; rEVO Biologics
- Class Alpha globulins; Anticoagulants; Antithrombins; Antithrombotics; Recombinant proteins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Antithrombin III deficiency; Blood coagulation disorders
Highest Development Phases
- Marketed Antithrombin III deficiency
- Phase III Blood coagulation disorders; Preeclampsia
- Discontinued Acute lung injury; Burns; Disseminated intravascular coagulation; Solid tumours
Most Recent Events
- 15 Apr 2021 No development reported - Preregistration for Antithrombin III deficiency in Canada (IV)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Coagulation-disorders(In neonates) in USA (Parenteral)
- 01 Nov 2016 rEVO Biologics completes a phase III trial in Preeclampsia in USA (IV) (NCT02059135)